682
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
THE IMPACT OF CORONAVIRUS INFECTION ON SABP DYNAMICS IN PATIENTS
WITH HYPERTENSION
Majidov Sharifjon Xusenovich
Osiyo xalqaro universitetida Assistent
E-mail:
https://doi.org/10.5281/zenodo.14709217
Abstract. When the risk factors of cardiovascular diseases come together, it can lead to
diseases with damage to many blood vessels. Due to the specific location of the coronary stenosis
zone in ischemic KMP, it leads to a sharp violation of vascular permeability, which in turn causes
damage to a large part of the myocardium, resulting in severe ischemic stress and pain that is
accompanied by a decrease in myocardial capacity. It is manifested by a complex of symptoms
[1]. Thus, identifying the main risk factors (trigger factors) of the development of IKMP and
predicting (predicting) the development of IKMP in patients with ischemic heart disease is an
important link in the primary and secondary prevention of ischemic heart disease [2].
Keywords: myocardial infarction, dilatation, ischemia, hypertension, hibernation,
inflammation, left ventricle, right ventricle, COVID19.
ВЛИЯНИЕ КОРОНАВИРУСНОЙ ИНФЕКЦИИ НА ДИНАМИКУ САД У
БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ
Аннотация. Когда факторы риска сердечно-сосудистых заболеваний
объединяются, это может привести к заболеваниям с поражением многих кровеносных
сосудов. В связи со спецификой расположения зоны коронарного стеноза при
ишемическом КМП происходит резкое нарушение проницаемости сосудов, что в свою
очередь вызывает повреждение значительной части миокарда, что приводит к
выраженному ишемическому напряжению и боли, что сопровождается снижением в
емкости миокарда. Проявляется комплексом симптомов [1]. Таким образом, выявление
основных факторов риска (триггерных факторов) развития ВМК и прогнозирование
(предсказание) развития ВМК у больных ишемической болезнью сердца является важным
звеном первичной и вторичной профилактики ишемической болезни сердца [2].
Ключевые слова: инфаркт миокарда, дилатация, ишемия, гипертония,
гибернация, воспаление, левый желудочек, правый желудочек, COVID19.
According to the research design, 74 patients were recruited. The average age of patients
was 53.54±1.92 years, the average duration of hypertension was 8.61 years. In the general group,
the initial SAB was 158.87±16.04 mm.s.ust, DAB was 96.15±8.34 mm.s.ust, and the average AB
was 117.06±9.33 mm.s.ust. Depending on the history of coronavirus infection, the patients were
683
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
divided into 2 groups: group I - hypertensive patients who had COVID19 (COVID19 (+)) one
month before inclusion in the study (n=42) and group II - hypertensive patients who did not have
COVID19 (COVID19(-)). The initial indicators of SAB and DAB did not differ in both groups
(Table 2.1). It should also be noted that both groups were matched for age and did not differ in
such parameters as BMI, LVH, LVDD and the number of patients with dyslipidemia. It should be
noted that the duration of hypertension was significantly longer in the group of patients with
COVID19 (+) hypertension. During 6 months of AGT, against the background of stabilization of
SAB and DAB, a significant improvement in the general clinical condition of patients was
observed, which was associated with a decrease in headache, dizziness and heaviness in the back
of the head. The drugs were well tolerated by patients, no significant adverse events were observed.
By the end of 6 months of therapy in the general group (Table 3.1), the degree of decrease
in office SAB values was -21.2±7.7%, DBP -17.8±8.7%, mean blood pressure - 19.99± 6.6%, in
all cases p=0.000. At the same time, the target values of SAB were achieved in 71 (96.0%), DAB
- in 70 (95.0%), SAB and DAB simultaneously in 72 (97.0%). In the group of patients with
hypertension, COVID19(+) AGT was generally characterized by satisfactory clinical efficacy and
tolerability.
The degree of reduction in SBP, DBP and mean BP: 21.6±7.97%, 17.8±7.9%, 19.5±6.5%,
in all cases p=0.005
Target values of SAB were achieved in 39 (93%), DAB in 40 (95.0%), SAB and DAB
simultaneously in 40 (95%) patients. In the group of patients with hypertension COVID19(-), AGT
was also characterized by satisfactory clinical efficacy. The degree of reduction in SAB, DAB and
mean PB: 22.8±7.3%, 18.4±9.8%, 20.6±6.8%, in all cases p=0.000. Target values of SAB were
achieved in 32 (100%), DAB in 30 (94.0%), SAB and DAB simultaneously in 32 (100%) patients.
Comparatively, no differences were found in the dynamics of blood pressure indicators in
both groups (Fig. 1). Both groups had high antihypertensive efficacy.
Table 1. Dynamics of office blood pressure parameters in patients with and without
COVID-19 with hypertension against the background of 6 months of antihypertensive therapy.
In general, positive dynamics of SPAB indicators were observed in both groups of
COVID19(+) and COVID19(-) patients with hypertension. In particular, the average daily,
average daytime and average nighttime indicators of SAB and DAB, as well as the increased
daytime and evening indicators of the loading index SAB and DAB significantly decreased
against the background of 6 months of AGT (Table 3.2). In addition, the average daily SAB
indicators in the group of COVID19(+) patients with AG initially amounted to 135.38±10.25
mm.s.s., and in dynamics – 127.0±5.73 mm.s.s. (p<0.05). In the group of patients with arterial
hypertension COVID19(-) - 133.43±20.44 mm.sym.ust, in dynamics 127.86±16.8 mm.sym.ust
684
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
(p<0.05); In the group of patients with COVID19(+) - AG, the average daytime SAB was initially
137.25±10.93 mm.sym.ust, in dynamics - 128.5±5.48 mm.sym.ust (p<0.05). In the group of
patients with COVID19(-) AG - 136.0±21.36 mm.sym.ust, in dynamics 128.0±9.5 mm.sym.ust
(p<0.02); Average daytime DAB in the group of patients with arterial hypertension COVID19(+)
was initially 88.88±7.51 mm.s.m.s., in dynamics – 82.25±7.05 mm.s.m.s. (p<0.05), in the group
of patients with AG COVID19(-) was initially 92.0±17.57 mm.s.m.s. . in dynamics 82.6±9.10
mm.s.m.s. (p<0.05); Average nighttime SAB values in the group of patients with AG
COVID19(+) were initially 129.12±9.57 mm.s.m.s. , in dynamics – 121.38±9.71 mm.s.m.s.
(p<0.02), in the group of patients with AG COVID19(-) – 127.57±18.27 mm.s.m.s., in dynamics
120.57±19.91 mm.s.m.s. (р<0.05); The average nighttime DAD in the group of COVID19(+)
patients with AG was initially 83.25±11.04 mm.sym.sup., in dynamics - 70.75±7.81
mm.sym.sup. (p<0.001), in the group of COVID19(-) patients with AG - 83.86±14.8
mm.sym.sup., in dynamics - 65.0±18.2 mm.sym.sup. (p<0.02).
The daytime and nighttime load index values decreased, the daytime load index decreased
significantly and reached normal values. In particular, in the group of patients with COVID19(+)
hypertension, the daytime INSAB index was initially 36.08±28.11 mm Hg. In dynamics, it was
16.0±10.56 mm Hg (p<0.05) In the group of patients with arterial hypertension COVID19(-)
Indicator
General
group,
n=74
COVID19(+)
n=43
COVID19(-)
n=32
SAB (mm.sim.ust)
158.87±16.0
4
157.02±14.01
161.30±18.30
123.24±10.6
6
*
123.10±10.47
*
123.44±7.23
*
DAB (mm.sim.ust)
96.15±8.34
95.83±8.26
96.56±8.56
78.29±6.25
*
78.33±8.91
*
78.24±6.76
*
Mid AB (mm.sim.ust)
117.06±9.33
116.23±8.76
118.14±10.06
93.27±6.64
*
93.25±7.12
*
93.31±6.09
*
YQS , ta/min
±1
78.74±8.82
80.29±10.84
76.53±4.61
70.88±3.93
*
71.10±4.27
*
70.41±3.43
*
∆% SAB
21.236±7.69
21.16±7.97
22.815±7,34
∆% DAB
17.780±8.71
17.81±7.91
18.375±9,77
∆% mid AB
-
19.989±6.61
-19.50±6.49
-20.619±6,85
Target
achieved
SAB
71 (96%)
39 (93%)
32 (100%)
DAB
70 (95%)
40 (95%)
30 (94%)
SAB+DAB
72 (97%)
40 (95%)
32 (100%)
685
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
initially - 35.6±13.96 mm Hg, in dynamics, it was 16.32±17.1 mm Hg (p<0.02); The daytime
INDAB index in patients with arterial hypertension who had COVID-19 was initially 46.0±25.76
mm.s.m.s., in dynamics - 12.6±14.8 mm.s.m.s. (p<0.001) and in the group of patients with arterial
hypertension who did not have COVID-19, it was initially 54.4±28.43 mm.s.m.s., in dynamics -
12.1±19.1 mm.s.m.s. (p<0.05); The nocturnal INSAB in the group of patients with arterial
hypertension COVID19(+) was initially 69.0±16.9 mm.s.m.s., in dynamics - 54.2±18.38
mm.s.m.s. (p<0.05) and in the group of patients with arterial hypertension COVID19(-) -
74.4±30.95 mm.s.m.s., respectively, in dynamics - 56.16±29.08 mm.s.m.s. (p<0.05); The
nocturnal INSAB indicator in patients with arterial hypertension COVID19(+) was initially
48.42±28.47 mm.s.m.s. In dynamics – 21.2±28.5 mm.s.m.s. (p<0.02) and in the group of patients
with arterial hypertension COVID19(-) – 53.2±36.49 mm.s.m.s. and, accordingly, in dynamics –
20.9±26.5 mm.s.m.s. (p<0.05).
It should be noted that the average DAB variability, diurnal SAB variability and diurnal
DAB variability were significantly reduced only in the group of patients with arterial
hypertension who did not have COVID19 (-). Also, the average DAB variability in the group of
patients who did not have COVID19 (-) was initially 13.8±2.86 mm.s.m.s.; in dynamics –
10.5±2.61 mm.s.m.s. (p<0.02); The daytime SAB variability in the same group was initially
15.7±3.86 mm.s.m.s.; in dynamics – 11.54±1.44 mm.s.m.s. (p<0.02); The daytime DAB
variability was initially 12.98±3.33 mm.s.m.s., in dynamics – 9.32±1.12 mm.s.m.s. (p<0.001). It
should also be noted that in terms of the degree of nocturnal decrease in SAB (СНС САД), a
sharp improvement in nocturnal blood pressure was observed with a high degree of reliability in
the group of patients with COVID19(-) hypertension, which initially amounted to 5.31±5.88
mm.sym.ust, in dynamics – 11.6±3.81 mm.sym.ust (p<0.001), reaching standard values.
REFERENCES
1.
Saodat, A., Vohid, A., Ravshan, N., & Shamshod, A. (2020). MRI study in patients with
idiopathic cokearthrosis of the hip joint.
International Journal of Psychosocial
Rehabilitation
,
24
(2), 410-415.
2.
Axmedov, S. J. (2023). EFFECTS OF THE DRUG MILDRONATE.
Innovative
Development in Educational Activities
,
2
(20), 40-59.
3.
Jamshidovich, A. S. (2023). ASCORBIC ACID: ITS ROLE IN IMMUNE SYSTEM,
CHRONIC INFLAMMATION DISEASES AND ON THE ANTIOXIDANT
EFFECTS.
EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
,
3
(11),
57-60.
686
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
4.
Jamshidovich, A. S. (2023). THE ROLE OF THIOTRIAZOLINE IN THE
ORGANISM.
Ta'lim innovatsiyasi va integratsiyasi
,
9
(5), 152-155.
5.
Jamshidovich,
A.
S.
(2023).
HEPTRAL
IS
USED
IN
LIVER
DISEASES.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
35
(3),
76-78.
6.
Jamshidovich, A. S. (2023). EFFECT OF TIVORTIN ON CARDIOMYOCYTE CELLS
AND ITS ROLE IN MYOCARDIAL INFARCTION.
Gospodarka i Innowacje.
,
42
, 255-
257.
7.
Jamshidovich,
A.
S.
(2024).
NEUROPROTECTIVE
EFFECT
OF
CITICOLINE.
EUROPEAN
JOURNAL
OF
MODERN
MEDICINE
AND
PRACTICE
,
4
(1), 1-4.
8.
Jamshidovich, A. S. (2024). THE ROLE OF TRIMETAZIDINE IN ISCHEMIC
CARDIOMYOPATHY.
Journal of new century innovations
,
44
(2), 3-8.
9.
Jamshidovich,
A.
S.
(2024).
ВСЕ
ЭФФЕКТЫ
ПРЕПАРАТА
ИМУДОН.
TADQIQOTLAR
,
31
(2), 39-43.
10.
Jamshidovich, A. S. (2024). SPECIFIC FEATURES OF THE EFFECT OF THE HEPARIN
DRUG.
TADQIQOTLAR
,
31
(2), 34-38.
11.
Jamshidovich, A. S. (2024). USE OF GLUCOCORTICOSTEROIDS IN PEDIATRIC
PRACTICE.
TADQIQOTLAR
,
31
(2), 29-33.
12.
Jamshidovich, A. S. (2024).
РОЛЬ ИНТЕЛЛАНОВОГО СИРОПА И
ЦИАНОКОБАЛАМИНА В УЛУЧШЕНИИ ПАМЯТИ.
TADQIQOTLAR
,
31
(2), 44-48.
13.
Jamshidovich, A. S. (2024). TREATMENT OF POLYNEUROPATHY WITH
BERLITHION.
Ta'limning zamonaviy transformatsiyasi
,
4
(1), 201-209.
14.
Jamshidovich, A. S. (2024). USE OF ASCORIL IN BRONCHIAL ASTHMA.
Ta'limning
zamonaviy transformatsiyasi
,
4
(1), 191-200.
15.
Jamshidovich, A. S. (2024). THE IMPORTANCE OF THE DRUG ARTOXAN.
Ta'limning
zamonaviy transformatsiyasi
,
4
(1), 182-190.
16.
Jamshidovich, A. S. (2024). THE ROLE OF RENGALIN IN CHRONIC
BRONCHITIS.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 116-123.
17.
Jamshidovich, A. S. (2024). THE ROLE OF ALMAGEL DRUG IN GASTRIC AND
DUODENAL WOUND DISEASE.
Ta'limning zamonaviy transformatsiyasi
,
4
(1), 173-
181.
687
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
18.
Jamshidovich, A. S. (2024). THE ROLE OF CODELAK BRONCHO SYRUP IN
CHILDREN'S PRACTICE.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 109-115.
19.
Jamshidovich, A. S. (2024). THE AEVIT DRUG EFFECT.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(4), 124-132.
20.
Jamshidovich, A. S. (2024). THE IMPORTANCE OF ALCHEBA DRUG IN POST-
STROKE APHASIA.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 132-138.
21.
Jamshidovich, A. S. (2024). THE ROLE OF HYALURON CHONDRO DRUG IN
OSTEOARTHROSIS.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 139-145.
22.
Jamshidovich, A. S. (2024). EFFECT OF SIMETHICONE DROP IN
FLATULENCE.
Лучшие интеллектуальные исследования
,
14
(1), 95-101.
23.
Jamshidovich, A. S. (2024). BENEFITS OF BETADINE SOLUTION.
Лучшие
интеллектуальные исследования
,
14
(1), 116-122.
24.
Jamshidovich, A. S. (2024). EFFECT INHALED GLUCOCORTICOIDS IN CHRONIC
OBSTRUCTIVE
PULMONARY
DISEASE
AND
BRONCHIAL
ASTHMA.
TADQIQOTLAR
,
31
(1), 171-180.
25.
Jamshidovich, A. S. (2024). USE OF VIGANTOL IN RICKETS.
Лучшие
интеллектуальные исследования
,
14
(1), 102-108.
26.
Jamshidovich, A. S. (2024). THE VITAPROST DRUG RESULTS.
Лучшие
интеллектуальные исследования
,
14
(1), 109-115.
27.
Jamshidovich, A. S. (2024). THE ROLE OF BISEPTOL DRUG IN URINARY TRACT
DISEASE.
Лучшие интеллектуальные исследования
,
14
(1), 89-94.
28.
Jamshidovich,
A.
S.
(2024).
PROPERTIES
OF
THE
DRUG
DORMIKIND.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(5), 88-92.
29.
Jamshidovich, A. S., & Komilovich, E. B. (2024). IMMUNOMODULATORY
FUNCTION OF DIBAZOL DRUG.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ
ИДЕИ В МИРЕ
,
38
(5), 83-87.
30.
Jamshidovich, A. S., & Komilovich, E. B. (2024). ADVANTAGES OF THE DRUG
HEPTRAL.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(5),
98-101.
688
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
31.
Эргашов, Б. К., & Ахмедов, Ш. Ж. (2024). ГИПЕРТОНИЧЕСКАЯ БОЛЕЗНЬ
ЭТИОЛОГИЯ.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(6), 59-69.
32.
Komilovich, E. B., & Jamshidovich, A. S. (2024). HYPERTENSION, CLASSIFICATION
AND PATHOGENESIS.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(6), 50-58.
33.
Komilovich, E. B., & Jamshidovich, A. S. (2024). YURAK ISHEMIYASI.
STENOKARDIYADA SHOSHILINCH TIBBIY YORDAM.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6), 12-20.
34.
Komilovich, E. B., & Jamshidovich, A. S. (2024). HYPERTENSION
ETIOLOGY.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6),
32-41.
35.
Komilovich, E. B., & Jamshidovich, A. S. (2024). CARDIAC ISCHEMIA. ANGINA
NURSING DIAGNOSIS AND CARE.
Journal of new century innovations
,
46
(1), 44-52.
36.
Jamshidovich, A. S. (2024). IMPORTANT INDICATIONS OF THE DRUG
WOBENZYM.
Journal of new century innovations
,
46
(1), 29-32.
37.
Jamshidovich, A. S. (2024). THE RESULTS OF THE EFFECT OF THE DRUG
VALIDOL.
Journal of new century innovations
,
46
(1), 19-23.
38.
Jamshidovich, A. S. (2024). VIFERON USE IN CHILDREN.
Journal of new century
innovations
,
46
(1), 24-28.
39.
Jamshidovich, A.
S.
(2024).
USE
OF
DUSPATALIN
(MEBEVERINE
HYDROCHLORIDE) IN GASTROINTESTINAL DISEASES.
ОБРАЗОВАНИЕ НАУКА
И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(5), 93-97.
40.
Jamshidovich, A. S. (2024). ЭФФЕКТЫ СИРОПА ДЕПАКИНА (ВАЛЬПРОЕВАЯ
КИСЛОТА).
Ta'lim innovatsiyasi va integratsiyasi
,
14
(2), 148-152.
41.
Jamshidovich, A. S., & Komilovich, E. B. (2024). THE IMPORTANCE OF THE DRUG
ALLOCHOL
FOR
CHRONIC
CHOLECYSTITIS.
Ta'lim
innovatsiyasi
va
integratsiyasi
,
14
(2), 133-137.
42.
Jamshidovich, A. S., & Komilovich, E. B. (2024). ВАЖНЫЕ СВОЙСТВА ПРЕПАРАТА
ДЕ-НОЛ (субцитрат висмута).
Ta'lim innovatsiyasi va integratsiyasi
,
14
(2), 143-147.
43.
Jamshidovich, A. S., & Komilovich, E. B. (2024). SPECIAL FEATURES OF BUDECTON
DRUG.
Ta'lim innovatsiyasi va integratsiyasi
,
14
(2), 138-142.
44.
Jamshidovich, A. S. (2024). ЭФФЕКТИВНОЕ ВОЗДЕЙСТВИЕ ПРЕПАРАТА
КЕЙВЕР.
Ta'lim innovatsiyasi va integratsiyasi
,
15
(3), 137-143.
689
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
45.
Jamshidovich, A. S. (2024). USEFUL PROPERTIES OF THE DRUG YODOFOL.
Ta'lim
innovatsiyasi va integratsiyasi
,
15
(3), 144-149.
46.
Jamshidovich, A. S. (2024). FITOTERAPIYANING AKUSHER-GINEKOLOGIYADA
AHAMIYATI.
Лучшие интеллектуальные исследования
,
15
(2), 121-125.
47.
Jamshidovich, A. S. (2024). THE IMPORTANCE OF THE DRUG DOPROKIN.
Лучшие
интеллектуальные исследования
,
15
(2), 109-114.
48.
Jamshidovich, A. S. (2024). THE EFFECT OF DOSTINEX ON THE BODY.
Лучшие
интеллектуальные исследования
,
15
(2), 115-120.
49.
Jamshidovich, A. S. (2024). РЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ
ПРЕПАРАТА КАНЕФРОН.
Лучшие интеллектуальные исследования
,
15
(2), 138-
143.
50.
Jamshidovich, A. S. (2024). СОВРЕМЕННЫЕ ЭФФЕКТЫ ПРЕПАРАТА
ИНДОЛ.
Лучшие интеллектуальные исследования
,
15
(2), 126-131.
51.
Jamshidovich, A. S. (2024). EFFECT OF ISMIZHEN DRUG ON BODY
IMMUNITY.
Лучшие интеллектуальные исследования
,
15
(2), 132-137.
52.
Jamshidovich, A. S. (2024). POSITIVE EFFECTS OF THE DRUG CARCIL.
Ta'lim
innovatsiyasi va integratsiyasi
,
15
(3), 127-131.
53.
Jamshidovich, A. S. (2024). PЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ
KАВИНТОНА.
Ta'lim innovatsiyasi va integratsiyasi
,
15
(3), 132-136.
54.
Jamshidovich, A. S. (2024). Современный Эффект Спрея Мометазон.
Research Journal
of Trauma and Disability Studies
,
3
(3), 62-65.
55.
Jamshidovich, A. S. (2024). THE ROLE OF" SIMONTE PLUS" DRUG IN THE
MODERN TREATMENT OF BRONCHIAL ASTHMA.
EUROPEAN JOURNAL OF
MODERN MEDICINE AND PRACTICE
,
4
(5), 66-70.
56.
Jamshidovich, A. S. (2024). FEATURES OF THE BIOMECHANISM OF THE DRUG
LEVOMYCETIN (CHLORAMPHENICOL).
EUROPEAN JOURNAL OF MODERN
MEDICINE AND PRACTICE
,
4
(9), 298-301.
57.
Jamshidovich, A. S. (2024). THE MOST IMPORTANT INDICATORS OF OMEGA 3
SUBSTANCE IN THE METABOLISM OF THE HUMAN BODY.
EUROPEAN
JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(10), 113-117.
58.
Komilovich, E. B., & Khalimovich,
M. N. (2024). CARDIAC ISCHEMIA. ANGINA
CLINICAL FORMS AND DIAGNOSIS.
Journal of new century innovations
,
46
(1), 70-78.
59.
Komilovich, E. B. (2024). CORONARY HEART DISEASE. ANGINA EMERGENCY
CARE.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(7), 235-
242.
690
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
60.
Komilovich, E. B. (2024). YURAK ISHEMIK KASALLIGI. STENOKARDIYANI
DAVOLASHNING ZAMONAVIY TAMOYILLARI.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6), 3-11.
61.
Komilovich, E. B., & Khalimovich, M. N. (2024). DEPENDENCIES IN THE CLINIC
AND DIAGNOSIS OF CORONARY HEART DISEASE AND ARTERIAL
HYPERTENSION.
Journal of new century innovations
,
46
(1), 61-69.
62.
Komilovich, E. B., & Xalimovich, M. N. (2024). YURAK ISHEMIYASIDA
HAMSHIRALIK DIAGNOSTIKASI VA PARVARISHI.
Journal of new century
innovations
,
46
(1), 79-85.
63.
Komilovich, E. B., & Khalimovich, M. N. (2024). NURSING CARE FOR CORONARY
ARTERY DISEASE, ANGINA PECTORIS.
Journal of new century innovations
,
46
(1),
86-94.
64.
Jamshidovich, A. S. (2024). THE MOST IMPORTANT BENEFITS OF GINGER FOR
THE HUMAN BODY'S IMMUNITY.
EUROPEAN JOURNAL OF MODERN MEDICINE
AND PRACTICE
,
4
(11), 269-273.
65.
Axmedov, S. (2024). THE SPECIFIC EFFECT OF THE DRUG" BAKLASAN" IN
CEREBROVASCULAR DISEASES AND ITS PRACTICAL SIGNIFICANCE
TODAY.
Modern Science and Research
,
3
(12), 485-492.
66.
Axmedov, S. (2025). ВАЖНЫЕ СВОЙСТВА ПРЕПАРАТА ЭСКУЗАН ПРИ
СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ.
Modern Science and Research
,
4
(1), 380-387.
67.
Xusenovich, M. S., & Turаpjаnovnа, Z. M. (2024). SEMIZLIKNING TURLI
FENOTIPLARDA
KARDIOMETABOLIK
XAVF
OMILLARINI
TAQQOSLASH.
SO‘NGI ILMIY TADQIQOTLAR NAZARIYASI
,
7
(4), 112-116.
68.
Husenovich, M. S., & Turabdjanovna, Z. M. (2024). STUDY OF DIURNAL PROFILE
OF
ARTERIAL
HYPERTENSION
IN
DIFFERENT
PHENOTYPE
OBESITY.
образование наука и инновационные идеи в мире
,
43
(1), 129-131.
69.
Xusenovich, M. S. (2024, September).
SEMIZLIKNI TURLI FENOTIPLARIDA YURAK
QON-TOMIR KASALLIKLARINI KELIB CHIQISH XAVFI PROGNOZI. In
INTERNATIONAL
SCIENTIFIC RESEARCH CONFERENCE
(Vol. 3, No. 26, pp. 15-18).
70.
Xusenovich, M. S. (2024). O ‘ZBEKISTONDA RESPUBLIKASIDA YURAK-QON
TOMIR KASALLIKLARI TARQALISHI VA HOZIRGI KUNDAGI KO’RILAYOTGAN
CHORA TADBIRLAR.
AMERICAN JOURNAL OF SOCIAL SCIENCE
,
2
(3), 79-82.
71.
Xusenovich, M. S., & Allayarovich, A. A. (2024). O ‘ZBEKISTONDA YURAK-QON
TOMIR
KASALLIKLARI
TARQALISHI
VA
HOZIRGI
KUNDAGI
691
ResearchBib IF - 11.01, ISSN: 3030-3753, Valume 2 Issue 1
TENDENSIYASI.
MODELS AND METHODS FOR INCREASING THE EFFICIENCY
OF INNOVATIVE RESEARCH
,
4
(38), 54-57.
72.
Ravshanovna, X. L. (2021, June). MINIMALLY INVASIVE METHODS OF
TREATMENT OF DENTAL CARIES IN ADULTS. In
" ONLINE-CONFERENCES"
PLATFORM
(pp. 118-119).
